Potential predictive value of hepatocyte growth factor (HGF) in advanced non-small cell lung cancer (NSCLC) treated with a platinum doublet and bevacizumab.

e22000 Background: Angiogenesis is implicated in disease progression/poor clinical outcome in multiple carcinomas, including lung cancer. Predictive biomarkers for bevacizumab and other anti-angiogenic agents have not been identified to aid in directing Tx decisions for frontline NSCLC patients. We evaluated a panel of serum biomarkers in non-squamous NSCLC patients immediately preceding treatment with chemotherapy with or without bevacizumab, at the discretion of the treating physician. Methods: Pretreatment (pre-Tx) serum from 68 Pts with frontline stage IV NSCLC were evaluated with the Human Angiogenesis Growth Factor Panel (EMD Millipore) containing angiopoietin-2, BMP-9, EGF, endoglin, endothelin-1, FGF-1, FGF-2, follistatin, G-CSF, HB-EGF, HGF, IL-8, leptin, PLGF, VEGF-A, VEGF-C, and VEGF-D on a FlexMAP 3D system (Luminex Corp.). Pts were treated with either standard platinum doublets (CTx; n=42) or CTx with bevacizumab (CTx+bev; n=26) according to physician choice. Disease responses were defined by...